Education/Professional Experience

    Sep.1980-Jul.1986  Norman Bethune Medical University English class of Clinical medine,  bachelordegree

    Sep.1986-Jul.1989  Norman Bethune Medical University Oncology,  Masterdegree

    Sep.2001-Jul.2004  Dalian Medical University Molecular biology,  Ph.D.

    Sep.1989.7up to now  The First Affiliated Hospital of Dalian Medical University Department of Oncology,Professor andDepartment Director

    Jun.1998-Dec.1998 Japan KitakyushuMedical Center Cancer center,  Visiting scholar

    Oct.2006-Mar.2007  Northwestern University, USA Robert Lurrie cancer center, Visiting scholar

    Participation in the Academic Community

    Standing Committee member of the Chinese society of Clinical Oncology (CSCO)

    Committeemember of Chemotherapy, Chinese Anti-cancer Association

    Vice Chairman of Small cell lung cancer expert committee-CSCO

    Vice Chairman of Cancer Society of Liaoning Province, Chinese Medical Association

    Vice Chairman of ChemotherapyCommittee,Liaoning Anti-cancer Association

    Committeemember of Oncologist, Chinese Medical Doctor Association

    Publication

    1. Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation. PLOS ONE, 2014, 9 (12): e115401. IF：3.534, Corresponding author

    doi: 10.1371/journal.pone.0115401. 

    2. Ginsenoside Rg3-induced EGFR/MAPK pathway deactivation inhibits melanoma cells proliferation via decreasing of FUT4/LeY expression. Int J Oncol. 2015, 46 (4): 1667-76. IF：3.025, Corresponding author; doi: 10.3892/ijo.2015.2886. 

    3. Ginsenoside Rg3 suppresses FUT4 expression through inhibiting NF-κB/p65 signaling pathway to promote melanoma cell death. Int J Oncol. 2015, 47: 701-709. IF: 3.025, Corresponding author; doi: 10.3892/ijo.2015.3057.

    4. Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review.Cancer Biol Ther. 2015; 16 (2): 215-8. IF: 3.072, Corresponding author; doi: 10.4161/15384047.2014.962318.

    5. Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4. Oncotarget ,2016, 7(2):1619-1632.IF：6.359 ,Corresponding  author;DOI:10.18632/oncotarget.6451

    6. Ginsenoside Rg3 induces FUT4-mediated apoptosis in H. pylori CagA-treated gastric cancer cells by regulating SP1 and HSF1 expressions. Toxicol In Vitro,  2016 ,31:158-166. IF：2.903, Co-corresponding author;DOI:10.1016/j.tiv.2015.09.025

    7. Effects of cinobufacini injection on cell proliferation and the expression of topoisomerases in human HepG-2 hepatocellular carcinoma cells, 2015, MOLECULAR MEDICINE REPORTS,  Volume: 12; Issue: 1; Pages: 1598-1604; Impact Factor(JCR2014)  IF: 1.554, Co-corresponding author; DOI:10.3892/mmr.2015.3552

    Research Projects/Grants

    Principal Investigator of the National Natural Science Foundation of China-“Study on the mechanism of Rg3 on the effect of novel serum marker d-GM3 in the malignant melanoma metastasis”

    Admission Plan/Requirements

    One for Doctoral Candidate

    One for Master’s Degree Candidate